Novolog (pharm Up 1966) Ltd.TASE: NVLG

NVLG: Q3 2025 revenue and profit declined year-over-year, but all segments remained profitable

· Issued by Novolog (pharm Up 1966) Ltd.

Q3 2025 saw revenue of ₪483.6M and net income of ₪4.3M, with declines in both revenue and profitability year-over-year. The company remains profitable across all segments, maintains a strong cash position, and projects 2025 Adjusted EBITDA of ₪96–102M.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Novolog (pharm Up 1966)

All Novolog (pharm Up 1966) news releases